SAN DIEGO -- (BUSINESS WIRE) -- PHusis Therapeutics Inc. is pleased to announce that Dr. Robert Kramer has agreed to join its Board of Directors. Dr. Kramer is former Vice President and Head of Discovery for Oncology Therapeutics at Janssen Research & Development, LLC (the Pharmaceutical Division of Johnnson and Johnson). He was responsible for leading Global Discovery, focusing on aberrant signaling cascades in tumor cells, as well as epigenetic reprogramming and tumor immunology using both small molecule and protein-based large molecule approaches. In addition to his key role leading internal Discovery programs in the Oncology Therapeutic Area, Dr. Kramer was also a partner for the Johnson & Johnson Innovation Centers and Business Development teams.
Dr. Kramer joined Janssen Research & Development from Bristol-Myers Squibb (BMS), where he was VP Drug Discovery and Research site head in Princeton, NJ where he provided scientific leadership and strategic oversight for many preclinical Oncology and Immunology programs/projects that entered development, several of which have gone on to receive regulatory approvals for treating patients with chronic myeloid leukemia, breast cancer and melanoma. He was also a member of the BMS research management team, which was responsible for setting R&D priorities across all therapeutic areas, from target discovery through proof of clinical concept, and for continuously improving the drug discovery/development process.
Dr. Kramer earned his doctorate in Pharmacology from the University of Vermont. He completed his post-doctoral fellowship in Oncology at the National Cancer Institute, National Institutes of Health. Dr. Kramer has successfully secured federal research funding and has taught as an Assistant Professor at Harvard Medical School. Additionally, he serves on the Pharmacology Basic Science Committee of the Pharmaceutical Manufacturers Association and is the current Vice President and a founding member of the non-profit Cancer Molecular Therapeutics Research Association.
About PHusis Therapeutics Inc.
PHusis Therapeutics Inc., San Diego, CA, is developing novel therapies targeting the Pleckstrin Homology (PH)-domain of critical signaling proteins associated with difficult to treat cancers. PHusis approach has integrated high-throughput molecular docking to rapidly accelerate its discovery activities against novel high value therapeutic targets. PHusis has a number of discovery programs ongoing with its first drug candidate in IND enabling studies and selective mut-KRAS inhibitors in lead optimization.